Nausea
Recent clinical, regulatory, research and industry developments relating to this disease.
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q1 2027.
- 2 industry developments reported.
Clinical MilestonesView all 10Hide
- 2026-05-18Antiemetic Fosaprepitant To Remedy Nausea and VomitingResults expected Q1 2027
- 2026-04-27Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and VomitingResults expected Q4 2027
- 2026-10-31A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)Primary completion
- 2026-10-31An Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent ChemotherapyPrimary completion
- 2026-08-31Preoperative Ginger for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Double-Blind Randomized Controlled TrialPrimary completion
- 2026-08-14Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompleted
- 2026-07-31A Comparison Between Palonosetron Versus Granisetron As Postoperative Nausea and Vomiting Prophylaxis In Idiopathic Scoliosis Surgery: A Randomized Control TrialCompleted
- 2027-01-01Steroids for Rhinoplasty: Pain, Nausea, Edema and EcchymosisWithdrawn
Industry & MarketViewHide
- 2026-06-04Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority TrialTrial news · Journal of Clinical Oncology
- 2026-08-07U.S. Sees Big Jump in Nausea Cases Among Frequent Marijuana Users in the HospitalIndustry · MedPage Today — Gastroenterology
- 2027-01-01ClinicalSteroids for Rhinoplasty: Pain, Nausea, Edema and EcchymosisWithdrawn
- 2026-10-31ClinicalA Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)Primary completion
- 2026-10-31ClinicalAn Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent ChemotherapyPrimary completion
- 2026-08-31ClinicalPreoperative Ginger for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Double-Blind Randomized Controlled TrialPrimary completion
- 2026-08-14ClinicalAdding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompleted
- 2026-08-07IndustryU.S. Sees Big Jump in Nausea Cases Among Frequent Marijuana Users in the HospitalIndustry · MedPage Today — Gastroenterology
- 2026-07-31ClinicalA Comparison Between Palonosetron Versus Granisetron As Postoperative Nausea and Vomiting Prophylaxis In Idiopathic Scoliosis Surgery: A Randomized Control TrialCompleted
- 2026-06-04IndustryReduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority TrialTrial news · Journal of Clinical Oncology
- 2026-05-18ClinicalAntiemetic Fosaprepitant To Remedy Nausea and VomitingResults expected Q1 2027
- 2026-04-27ClinicalOlanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and VomitingResults expected Q4 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Generic approval — Palonosetron Accord is indicated in adults for: the prevention of acute nausea and vomit… (2016)
Original application approval — Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic c… (2012)
Original application approval — Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer… (2008)
Original application approval — Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vom… (2003)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Antibodies, Bispecific1
- Antidepressive Agents1
- Antineoplastic Agents, Immunological1
- Breast Neoplasms1
- Immunoconjugates1
- Nausea1
- Neoplasms1
- Neuregulin-11
Leading journals6
- The New England journal of medicine2
- Blood1
- Frontiers in endocrinology1
- JAMA1
- Neurogastroenterology and motility1
- The oncologist1
Leading researchers8
- Adeyemi S1
- Alesini D1
- Ballatore Z1
- Barberi V1
- Batterham RL1
- Bekaii-Saab T1
- Botticelli A1
- Burke JM1
Affiliations (unnormalised)6
- "S. Carlo" Hospital1
- "Sapienza" University of Rome1
- Abramson Cancer Center1
- AOU Policlinico Umberto I1
- Central Hospital of Belcolle1
- Chao Family Comprehensive Cancer Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Nausea is an unpleasant sensation in the stomach that is usually accompanied by an urge to vomit. It is a symptom rather than a disease entity and is commonly discussed in relation to physiopathology and therapy.
The supplied grounding identifies early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses as common causes of nausea. No additional causes are supported by the provided material.
The grounding supports nausea as a physiopathologic symptom, but it does not provide a detailed biological mechanism. It also notes co-study with trkB receptor and semaglutide, but no mechanism is described in the supplied abstracts that can be attributed specifically to nausea.
The provided material supports early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviral infections as factors associated with nausea. No broader risk-factor framework is supported beyond these common causes.
The supplied review material supports cannabinoid-based therapies as being studied for nausea and vomiting due to chemotherapy, indicating cannabinoids as a treatment modality in that context. It also notes semaglutide as a co-studied drug in relation to gastrointestinal side effects, but does not support semaglutide as a treatment for nausea.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.